Shares of Histogenics Corp (NASDAQ:HSGX) saw an uptick in trading volume on Wednesday . 3,878,478 shares changed hands during mid-day trading, an increase of 160% from the previous session’s volume of 1,490,342 shares.The stock last traded at $0.54 and had previously closed at $0.45.

Several research firms have recently commented on HSGX. Zacks Investment Research lowered Histogenics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 7th. HC Wainwright set a $1.00 price target on Histogenics and gave the stock a “buy” rating in a research report on Friday, November 9th. BTIG Research lowered Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 price target for the company. in a research report on Wednesday, September 5th. Needham & Company LLC boosted their price target on Histogenics to $5.00 and gave the stock a “buy” rating in a research report on Thursday, September 6th. Finally, Brookline Cap M reissued a “buy” rating on shares of Histogenics in a research report on Wednesday, August 1st. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Histogenics presently has a consensus rating of “Buy” and a consensus target price of $3.25.

The stock has a market capitalization of $27.91 million, a P/E ratio of -0.55 and a beta of 1.02.

Histogenics (NASDAQ:HSGX) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.05). On average, equities analysts anticipate that Histogenics Corp will post -0.22 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in Histogenics during the 3rd quarter worth $117,000. BlackRock Inc. grew its stake in Histogenics by 72.0% during the 2nd quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock worth $137,000 after buying an additional 22,927 shares during the last quarter. DRW Securities LLC purchased a new position in Histogenics during the 2nd quarter worth $242,000. JPMorgan Chase & Co. purchased a new position in Histogenics during the 1st quarter worth $320,000. Finally, Renaissance Technologies LLC grew its stake in Histogenics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock worth $961,000 after buying an additional 22,133 shares during the last quarter. 36.43% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/11/21/histogenics-hsgx-sees-unusually-high-trading-volume.html.

Histogenics Company Profile (NASDAQ:HSGX)

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Recommended Story: Trading Strategy Examples and Plans

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.